{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:14:25Z","timestamp":1763774065229,"version":"3.45.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.06.021","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:01:02Z","timestamp":1751634062000},"page":"e1022-e1032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Experience With Venetoclax-Based Therapy in Acute Myeloid Leukemia: Insights From the Czech Republic"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8095-7928","authenticated-orcid":false,"given":"Barbora","family":"Dluho\u0161ov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjam\u00edn","family":"V\u00ed\u0161ek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2248-0557","authenticated-orcid":false,"given":"Jan","family":"V\u00e1lka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"\u010cer\u0148an","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u013dubom\u00edr","family":"Mina\u0159\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1241-1635","authenticated-orcid":false,"given":"Jan","family":"Nov\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3303-4146","authenticated-orcid":false,"given":"Ji\u0159\u00ed","family":"\u0160r\u00e1mek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Mertov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolana","family":"Mertov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-7093","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Szotkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Jon\u00e1\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7735-8412","authenticated-orcid":false,"given":"Michal","family":"Karas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zden\u011bk","family":"Ko\u0159\u00edstek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2025.06.021_bib0001","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2025.06.021_bib0002","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz Keith","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.021_bib0003","doi-asserted-by":"crossref","unstructured":"Fuqua J, Abonofal A, Safi SUD. Effectiveness of intensive chemotherapy with 7+3 versus vidaza and venetoclax in acute myeloid leukemia with sequential stem cell transplant: results from real-world cohorts. 2023. 1487. https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper187949.html.","DOI":"10.1182\/blood-2023-187949"},{"key":"10.1016\/j.clml.2025.06.021_bib0004","series-title":"Filo Study","article-title":"161 acute myeloid leukemia patients who stopped venetoclax or\/and azacytidine for other reasons than progression have a prolonged treatment free remission and overall survival","author":"Garciaz","year":"2023"},{"issue":"12","key":"10.1016\/j.clml.2025.06.021_bib0005","first-page":"1345","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood, J Am Soc Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.021_bib0006","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.021_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low dose cytarabine in the UK NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.clml.2025.06.021_bib13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2023-187331","article-title":"Real World Use of Azacitidine and Venetoclax in Acute myeloid leukemia in Frontline and Relapse\/Refractory settings: a multicentric study from French Auraml Group","volume":"142","author":"Gross","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.06.021_bib0007","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.06.021_bib0008","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2024-200013","article-title":"Evaluation of venetoclax duration in venetoclax-azacitidine regimen for untreated acute myeloid leukemia: real world experience from hokkaido leukemia net","volume":"144","author":"Kanaya","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.021_bib0009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"21","key":"10.1016\/j.clml.2025.06.021_bib0012","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2025.06.021_bib0010","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502500237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502500237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:11:02Z","timestamp":1763773862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502500237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S215226502500237X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Experience With Venetoclax-Based Therapy in Acute Myeloid Leukemia: Insights From the Czech Republic","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}